{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T03:46:25Z","timestamp":1776743185663,"version":"3.51.2"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.clml.2025.10.019","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T02:12:33Z","timestamp":1762308753000},"page":"209-218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Outcomes in Myeloma Patients With t (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4424-634X","authenticated-orcid":false,"given":"Julia","family":"Varghese","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher P","family":"Venner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha","family":"Louzada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna","family":"Reece","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darrell","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Smriti","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiandong","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor H","family":"Jimenez-Zepeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arleigh","family":"McCurdy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0786-7961","authenticated-orcid":false,"given":"Kevin","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1584-1067","authenticated-orcid":false,"given":"Hira","family":"Mian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Sebag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Stakiw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2706-8764","authenticated-orcid":false,"given":"Anthony","family":"Reiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rami","family":"Kotb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Aslam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rayan","family":"Kaedbey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debra","family":"Bergstrom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Engin","family":"Gul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"LeBlanc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2025.10.019_bib0001","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41408-022-00679-5","article-title":"High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions","volume":"12","author":"Hagen","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2025.10.019_bib0002","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.leukres.2013.06.020","article-title":"t(11;14) multiple myeloma: a subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome","volume":"37","author":"An","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2025.10.019_bib0003","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.clml.2021.08.007","article-title":"Effect of t (11;14) abnormality on outcomes of patients with newly diagnosed multiple myeloma in the Connect MM registry","volume":"22","author":"Gasparetto","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2025.10.019_bib0004","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.10.019_bib0005","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.17627","article-title":"Impact of t(11;14) as a sole and concomitant abnormality on outcomes in multiple myeloma","volume":"195","author":"Bal","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2025.10.019_bib0006","first-page":"2950","article-title":"Multiple myeloma with t(11;14): unique biology and evolving landscape","volume":"12","author":"Bal","year":"2022","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.clml.2025.10.019_bib0007","doi-asserted-by":"crossref","unstructured":"Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis | blood | American Society of Hematology [Internet]. 2023. Available at: https:\/\/ashpublications.org\/blood\/article\/98\/7\/2266\/107138\/Translocations-involving-the-immunoglobulin-heavy.","DOI":"10.1182\/blood.V98.7.2266"},{"key":"10.1016\/j.clml.2025.10.019_bib0008","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/sj.bmt.1705857","article-title":"Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14)","volume":"40","author":"Hundemer","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2025.10.019_bib0009","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.3324\/haematol.2012.078519","article-title":"Extramedullary involvement in multiple myeloma","volume":"97","author":"Blad\u00e9","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2025.10.019_bib0010","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.2011.34.9290","article-title":"Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach","volume":"29","author":"Blad\u00e9","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.10.019_bib0011","doi-asserted-by":"crossref","unstructured":"Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants | blood | American Society of Hematology [Internet]. 2023. Available at: https:\/\/ashpublications.org\/blood\/article\/101\/4\/1570\/105950\/Translocation-t-11-14-q13-q32-is-the-hallmark-of.","DOI":"10.1182\/blood-2002-08-2436"},{"key":"10.1016\/j.clml.2025.10.019_bib0012","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-023-00807-9","article-title":"Multiple myeloma with t(11;14): impact of novel agents on outcome","volume":"13","author":"Puertas","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2025.10.019_bib0013","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/leu.2013.216","article-title":"The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma","volume":"28","author":"Touzeau","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.10.019_bib0014","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ajh.26083","article-title":"Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed\/refractory t(11;14) multiple myeloma","volume":"96","author":"Kaufman","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.10.019_bib0015","first-page":"10","article-title":"What multiple myeloma with t(11;14) should Be classified into in novel agent era: standard or intermediate risk?","author":"Gao","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2025.10.019_bib0016","doi-asserted-by":"crossref","first-page":"6997","DOI":"10.1038\/ncomms7997","article-title":"APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma","volume":"6","author":"Walker","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.clml.2025.10.019_bib0017","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2014.57.4947","article-title":"Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with Bortezomib-based regimens","author":"Bochtler","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.10.019_bib0018","doi-asserted-by":"crossref","first-page":"8015","DOI":"10.1200\/JCO.2019.37.15_suppl.8015","article-title":"Outcomes of patients with t(11;14) multiple myeloma: an International Myeloma Working Group (IMWG) multicenter study","volume":"37","author":"Durie","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.10.019_bib0019","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1182\/blood-2019-126015","article-title":"Updated analysis of Bellini, a phase 3 study of Venetoclax or Placebo in combination with Bortezomib and Dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"134","author":"Moreau","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.10.019_bib0020","doi-asserted-by":"crossref","first-page":"e491","DOI":"10.1016\/j.clml.2025.02.011","article-title":"Treatment patterns and outcomes of Multiple Myeloma patients undergoing second-line Therapy: a Canadian Myeloma Research Group (CMRG) analysis","volume":"25","author":"Mcurdy","year":"2025","journal-title":"J Clin Lymph Myeloma Leuk"},{"key":"10.1016\/j.clml.2025.10.019_bib0021","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1200\/JCO.21.00443","article-title":"Phase I study of Venetoclax plus Daratumumab and Dexamethasone, with or without Bortezomib, in patients with relapsed or refractory multiple myeloma with and without t(11;14)","volume":"39","author":"Bahlis","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.10.019_bib0022","doi-asserted-by":"crossref","unstructured":"Nizar J. Bahlis et al. Efficacy of venetoclax-dexamethasone (VenDex) v pomalidomide-dexamethasone (PomDex) in patients (Pts) with t(11;14)-positive relapsed\/refractory multiple myeloma [t(11;14)+ RRMM]: Phase 3 CANOVA study biomarker subgroup analysis.. J Clin Oncol 42, 7510-7510(2024).DOI:10.1200\/JCO.2024.42.16_suppl.7510","DOI":"10.1200\/JCO.2024.42.16_suppl.7510"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042685?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042685?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T03:17:35Z","timestamp":1776741455000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025042685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2152265025042685"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.10.019","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Outcomes in Myeloma Patients With t (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}